Big bucks shaved off CEO pay

Posted 28 June 2022 PM

More than half of the top-paid pharma CEOs saw their pay fall in 2021 compared to the previous year, in many cases due to unusually high bonuses in 2020 from Covid sales.

The total reported remuneration for the top 15 pharma CEOs was US$302.31 million, a third less than the total payout a year earlier. A large part of that was due to the extreme termination package of US$135.35 million given to Len Schleifer when he left Regeneron.

To see the whole article, please login